BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 29
• 30

• Press Releases

  Terns Announces Proposed Public Offering

  December 10, 2025

   · 

  5 min read
• Press Releases

  Alligator Bioscience Comments on Henlius Receiving Regulatory Approval in China to Initiate Phase 2/3 Trials of HLX22 in HER2-Positive Breast Cancer

  December 10, 2025

   · 

  2 min read
• Press Releases

  Saol Therapeutics Has Been Granted a Type A Meeting with the FDA to Determine the Path Forward for SL1009 in Pyruvate Dehydrogenase Complex Deficiency (PDCD)

  December 10, 2025

   · 

  3 min read
• 

  Regulatory

  Regeneron Climbs Back After a Year of Regulatory, Manufacturing Misery

  After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this summer—the lowest they’d been since early 2021. But they now sit higher than they did at the start of the year.

  December 10, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• Press Releases

  Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

  December 10, 2025

   · 

  5 min read
• Press Releases

  Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

  December 10, 2025

   · 

  2 min read
• Press Releases

  1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

  December 10, 2025

   · 

  13 min read
• Press Releases

  Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada

  December 10, 2025

   · 

  7 min read
• Press Releases

  ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science

  December 10, 2025

   · 

  4 min read
• Press Releases

  Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

  December 10, 2025

   · 

  6 min read